종양 절제 시장 규모, 점유율, 성장, 세계 산업 분석, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of tumor ablation Market

The global tumor ablation market size was valued at USD 846.8 million in 2025 and is projected to grow from USD 903.3 million in 2026 to USD 1,579.7 million by 2034, exhibiting a CAGR of 7.2% during the forecast period. North America dominated the global market with a 40.3% share in 2025. Tumor ablation is a minimally invasive treatment used for tumors affecting the liver, kidney, bone, and other organs. Growing cancer incidence, increasing procedure volumes, shorter recovery periods, reduced pain, and shorter hospital stays are supporting adoption.

Latest Trends

The market is witnessing a shift toward minimally invasive tumor treatment technologies, including microwave ablation, radiofrequency ablation, cryoablation, and other advanced techniques. Growing use of CT-, MRI-, and ultrasound-guided procedures is improving treatment precision. Integration of artificial intelligence, data analytics, and image guidance is also supporting better tumor targeting. Combination approaches involving ablation with immunotherapy and targeted therapies are emerging as another important trend.

Market Dynamics

DRIVER - Increasing Prevalence of Cancer:

The rising incidence of liver, lung, kidney, and other cancers is expanding the patient pool requiring localized tumor treatment. Aging populations and the growing number of patients who are unsuitable for major surgery are further supporting demand for minimally invasive ablation procedures.

RESTRAINT - High Cost of Advanced Products and Procedures:

Advanced ablation systems, disposable probes, imaging integration, and multimodality imaging support can increase procedure costs. Limited reimbursement and healthcare infrastructure in developing countries can restrict adoption.

MARKET OPPORTUNITY - Technological Advancements in Ablation Systems:

Innovations in imaging integration, automation, energy delivery, and non-thermal ablation are creating opportunities for improved safety and treatment precision. Product approvals and commercialization of technologies such as histotripsy are further expanding the opportunity landscape.

CHALLENGE - Limited Access in Emerging Countries:

Availability of advanced ablation equipment, specialized interventional radiologists, imaging infrastructure, and trained professionals remains limited in several emerging markets. Recurrence risks and competition from surgery, radiation, and systemic therapies also present challenges.

Segmentation Analysis

By Product Type:

The market is segmented into instruments and accessories. Accessories dominated in 2025, supported by increasing procedure volumes and product launches. The instruments segment is projected to grow at a CAGR of 7.2% during the forecast period.

By Technology:

Technologies include radiofrequency ablation, microwave ablation, cryoablation, high-intensity focused ultrasound, and others. Microwave ablation dominated in 2025 and is expected to account for a 34.9% share in 2026. The high-intensity focused ultrasound segment is projected to grow at a CAGR of 9.6%.

By Treatment Type:

The market includes surgical, laparoscopic, and percutaneous procedures. Percutaneous treatment dominated in 2025 with a 68.1% share, supported by increasing procedures for localized cancers. The surgical segment is expected to grow at a CAGR of 6.3%.

By Application:

Applications include lung cancer, liver cancer, kidney cancer, and others. Liver cancer dominated in 2025 with a 40.0% share. The kidney cancer segment is projected to grow at a CAGR of 6.7%.

By End User:

Hospitals & clinics, cancer care centers, and others constitute the end-user segments. Hospitals & clinics dominated in 2025 and are expected to hold a 67.2% share in 2026 due to high procedure volumes and advanced infrastructure. Cancer care centers are projected to grow at a CAGR of 7.7%.

Regional Outlook

North America led the market with USD 341.3 million in 2025. The U.S. market is estimated to reach USD 328.4 million in 2026, supported by cancer incidence, advanced healthcare infrastructure, reimbursement availability, and increasing ablation procedures.

Europe is projected to reach USD 287.8 million in 2026, supported by cancer prevalence, minimally invasive treatment adoption, and improving healthcare facilities. The U.K., Germany, and France are expected to reach USD 43.7 million, USD 54.1 million, and USD 43.9 million, respectively.

Asia Pacific is estimated to reach USD 203.3 million in 2026, making it the third-largest regional market. China and India are projected to reach USD 96.7 million and USD 22.3 million, respectively, supported by expanding interventional radiology capabilities.

Latin America is expected to reach USD 29.9 million in 2026, while GCC is projected to attain USD 9.7 million, supported by healthcare infrastructure development and increasing adoption of tumor ablation technologies.

Competitive Landscape

The market features technologically advanced companies focusing on product launches, regulatory approvals, collaborations, and acquisitions. Major players include Medtronic, Johnson & Johnson Services, Inc., Boston Scientific Corporation, AngioDynamics, Abbott, Focal One, Hologic, Inc., Stryker, Olympus Corporation, and Siemens Healthineers AG.

Investment Analysis & Opportunities

Investment opportunities are increasing across microwave ablation, cryoablation, laser ablation, histotripsy, image-guided systems, and non-thermal technologies. Companies are investing in R&D, strategic collaborations, and advanced imaging integration to improve treatment precision and expand clinical applications.

New Product Development

Product development is focused on improving energy delivery, imaging guidance, precision, and minimally invasive treatment capabilities. In July 2025, Varian launched its next-generation IntelliBlate microwave ablation solution in Europe for treating soft tumors. Medtronic also received FDA approval for its Visualase V2 MRI-Guided Laser Ablation System in June 2025.

Five Recent Developments

• October 2025: Monteris Medical collaborated with Symphony Robotics to advance MRI-guided neurosurgical ablation.
• June 2025: Medtronic received U.S. FDA approval for its Visualase V2 MRI-Guided Laser Ablation System.
• October 2024: AngioDynamics partnered with University College London Hospital for a multicenter study involving the NanoKnife System.
• March 2024: Clinical Laserthermia Systems Americas announced use of its TRANBERG Thermal Therapy System by ROSE Urology.
• March 2021: Avenda Health received U.S. breakthrough device designation for its Focal Therapy System.

Report Coverage

The Tumor Ablation Market Report provides comprehensive analysis of market size, market value, market trends, market dynamics, product types, technologies, treatment types, applications, end users, regional markets, and competitive developments. It also covers technological advancements, product launches, regulatory approvals, strategic collaborations, and other factors influencing market growth.

Conclusion

The global tumor ablation market is expanding as cancer prevalence increases and healthcare providers increasingly adopt minimally invasive treatment approaches. The market is projected to rise from USD 846.8 million in 2025 to USD 903.3 million in 2026 and reach USD 1,579.7 million by 2034. Advancements in image-guided ablation, microwave technology, cryoablation, laser systems, and emerging non-thermal therapies are expected to create further opportunities, while treatment costs, limited infrastructure, reimbursement limitations, and long-term clinical challenges remain important market considerations.

Global Tumor Ablation Market Scope

Segmentation By Product Type

• Instruments
• Accessories

By Technology

• Radiofrequency Ablation
• Microwave Ablation
• Cryoablation
• High Intensity Focused Ultrasound
• Others

By Treatment Type

• Surgical
• Laparoscopic
• Percutaneous

By Application

• Lung Cancer
• Liver Cancer
• Kidney Cancer
• Others

By End User

• Hospitals & Clinics
• Cancer Care Centers
• Others

By Region

• North America (By Product Type, By Technology, By Treatment Type, By Application, By End User, and by Country)
  • U.S. (By Product Type)
  • Canada (By Product Type)
• Europe (By Product Type, By Technology, By Treatment Type, By Application, By End User, and by Country/Sub-region)
  • U.K. (By Product Type)
  • Germany (By Product Type)
  • France (By Product Type)
  • Italy (By Product Type)
  • Spain (By Product Type)
  • Scandinavia (By Product Type)
  • Rest of Europe (By Product Type)
• Asia Pacific (By Product Type, By Technology, By Treatment Type, By Application, By End User, and by Country/Sub-region)
  • China (By Product Type)
  • Japan (By Product Type)
  • India (By Product Type)
  • Australia (By Product Type)
  • Southeast Asia (By Product Type)
  • Rest of Asia Pacific (By Product Type)
• Latin America (By Product Type, By Technology, By Treatment Type, By Application, By End User, and by Country/Sub-region)
  • Brazil (By Product Type)
  • Mexico (By Product Type)
  • Rest of Latin America (By Product Type)
• Middle East & Africa (By Product Type, By Technology, By Treatment Type, By Application, By End User, and by Country/Sub-region)
  • GCC (By Product Type)
  • South Africa (By Product Type)
  • Rest of the Middle East & Africa (By Product Type)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Key Disorders, Key Countries/Regions, 2023/2024
• 4.2. Technological Advancements in Tumor Ablation Procedures
• 4.3. New Product Launches, Key Players
• 4.4. Key Industry Developments - Mergers, Acquisitions & Partnerships

5. Global Tumor Ablation Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Product Type
  • 5.1.1. Instruments
  • 5.1.2. Accessories
• 5.2. Market Analysis, Insights and Forecast - By Technology
  • 5.2.1. Radiofrequency Ablation
  • 5.2.2. Microwave Ablation
  • 5.2.3. Cryoablation
  • 5.2.4. High Intensity Focused Ultrasound
  • 5.2.5. Others
• 5.3. Market Analysis, Insights and Forecast - By Treatment Type
  • 5.3.1. Surgical
  • 5.3.2. Laparoscopic
  • 5.3.3. Percutaneous
• 5.4. Market Analysis, Insights and Forecast - By Application
  • 5.4.1. Lung Cancer
  • 5.4.2. Liver Cancer
  • 5.4.3. Kidney Cancer
  • 5.4.4. Others
• 5.5. Market Analysis, Insights and Forecast - By End User
  • 5.5.1. Hospitals & Clinics
  • 5.5.2. Cancer Care Centers
  • 5.5.3. Others
• 5.6. Market Analysis, Insights and Forecast - By Region
  • 5.6.1. North America
  • 5.6.2. Europe
  • 5.6.3. Asia Pacific
  • 5.6.4. Latin America
  • 5.6.5. Middle East & Africa

6. North America Tumor Ablation Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Product Type
  • 6.1.1. Instruments
  • 6.1.2. Accessories
• 6.2. Market Analysis, Insights and Forecast - By Technology
  • 6.2.1. Radiofrequency Ablation
  • 6.2.2. Microwave Ablation
  • 6.2.3. Cryoablation
  • 6.2.4. High Intensity Focused Ultrasound
  • 6.2.5. Others
• 6.3. Market Analysis, Insights and Forecast - By Treatment Type
  • 6.3.1. Surgical
  • 6.3.2. Laparoscopic
  • 6.3.3. Percutaneous
• 6.4. Market Analysis, Insights and Forecast - By Application
  • 6.4.1. Lung Cancer
  • 6.4.2. Liver Cancer
  • 6.4.3. Kidney Cancer
  • 6.4.4. Others
• 6.5. Market Analysis, Insights and Forecast - By End User
  • 6.5.1. Hospitals & Clinics
  • 6.5.2. Cancer Care Centers
  • 6.5.3. Others
• 6.6. Market Analysis, Insights and Forecast - By Country
  • 6.6.1. U.S.
    • 6.6.1.1. By Product Type
  • 6.6.2. Canada
    • 6.6.2.1. By Product Type

7. Europe Tumor Ablation Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Product Type
  • 7.1.1. Instruments
  • 7.1.2. Accessories
• 7.2. Market Analysis, Insights and Forecast - By Technology
  • 7.2.1. Radiofrequency Ablation
  • 7.2.2. Microwave Ablation
  • 7.2.3. Cryoablation
  • 7.2.4. High Intensity Focused Ultrasound
  • 7.2.5. Others
• 7.3. Market Analysis, Insights and Forecast - By Treatment Type
  • 7.3.1. Surgical
  • 7.3.2. Laparoscopic
  • 7.3.3. Percutaneous
• 7.4. Market Analysis, Insights and Forecast - By Application
  • 7.4.1. Lung Cancer
  • 7.4.2. Liver Cancer
  • 7.4.3. Kidney Cancer
  • 7.4.4. Others
• 7.5. Market Analysis, Insights and Forecast - By End User
  • 7.5.1. Hospitals & Clinics
  • 7.5.2. Cancer Care Centers
  • 7.5.3. Others
• 7.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.6.1. U.K.
    • 7.6.1.1. By Product Type
  • 7.6.2. Germany
    • 7.6.2.1. By Product Type
  • 7.6.3. France
    • 7.6.3.1. By Product Type
  • 7.6.4. Spain
    • 7.6.4.1. By Product Type
  • 7.6.5. Italy
    • 7.6.5.1. By Product Type
  • 7.6.6. Scandinavia
    • 7.6.6.1. By Product Type
  • 7.6.7. Rest of Europe
    • 7.6.7.1. By Product Type

8. Asia Pacific Tumor Ablation Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Product Type
  • 8.1.1. Instruments
  • 8.1.2. Accessories
• 8.2. Market Analysis, Insights and Forecast - By Technology
  • 8.2.1. Radiofrequency Ablation
  • 8.2.2. Microwave Ablation
  • 8.2.3. Cryoablation
  • 8.2.4. High Intensity Focused Ultrasound
  • 8.2.5. Others
• 8.3. Market Analysis, Insights and Forecast - By Treatment Type
  • 8.3.1. Surgical
  • 8.3.2. Laparoscopic
  • 8.3.3. Percutaneous
• 8.4. Market Analysis, Insights and Forecast - By Application
  • 8.4.1. Lung Cancer
  • 8.4.2. Liver Cancer
  • 8.4.3. Kidney Cancer
  • 8.4.4. Others
• 8.5. Market Analysis, Insights and Forecast - By End User
  • 8.5.1. Hospitals & Clinics
  • 8.5.2. Cancer Care Centers
  • 8.5.3. Others
• 8.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.6.1. Japan
    • 8.6.1.1. By Product Type
  • 8.6.2. Australia
    • 8.6.2.1. By Product Type
  • 8.6.3. China
    • 8.6.3.1. By Product Type
  • 8.6.4. India
    • 8.6.4.1. By Product Type
  • 8.6.5. Southeast Asia
    • 8.6.5.1. By Product Type
  • 8.6.6. Rest of Asia Pacific
    • 8.6.6.1. By Product Type

9. Latin America Tumor Ablation Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Product Type
  • 9.1.1. Instruments
  • 9.1.2. Accessories
• 9.2. Market Analysis, Insights and Forecast - By Technology
  • 9.2.1. Radiofrequency Ablation
  • 9.2.2. Microwave Ablation
  • 9.2.3. Cryoablation
  • 9.2.4. High Intensity Focused Ultrasound
  • 9.2.5. Others
• 9.3. Market Analysis, Insights and Forecast - By Treatment Type
  • 9.3.1. Surgical
  • 9.3.2. Laparoscopic
  • 9.3.3. Percutaneous
• 9.4. Market Analysis, Insights and Forecast - By Application
  • 9.4.1. Lung Cancer
  • 9.4.2. Liver Cancer
  • 9.4.3. Kidney Cancer
  • 9.4.4. Others
• 9.5. Market Analysis, Insights and Forecast - By End User
  • 9.5.1. Hospitals & Clinics
  • 9.5.2. Cancer Care Centers
  • 9.5.3. Others
• 9.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.6.1. Brazil
    • 9.6.1.1. By Product Type
  • 9.6.2. Mexico
    • 9.6.2.1. By Product Type
  • 9.6.3. Rest of Latin America
    • 9.6.3.1. By Product Type

10. Middle East & Africa Tumor Ablation Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Product Type
  • 10.1.1. Instruments
  • 10.1.2. Accessories
• 10.2. Market Analysis, Insights and Forecast - By Technology
  • 10.2.1. Radiofrequency Ablation
  • 10.2.2. Microwave Ablation
  • 10.2.3. Cryoablation
  • 10.2.4. High Intensity Focused Ultrasound
  • 10.2.5. Others
• 10.3. Market Analysis, Insights and Forecast - By Treatment Type
  • 10.3.1. Surgical
  • 10.3.2. Laparoscopic
  • 10.3.3. Percutaneous
• 10.4. Market Analysis, Insights and Forecast - By Application
  • 10.4.1. Lung Cancer
  • 10.4.2. Liver Cancer
  • 10.4.3. Kidney Cancer
  • 10.4.4. Others
• 10.5. Market Analysis, Insights and Forecast - By End User
  • 10.5.1. Hospitals & Clinics
  • 10.5.2. Cancer Care Centers
  • 10.5.3. Others
• 10.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.6.1. GCC
    • 10.6.1.1. By Product Type
  • 10.6.2. South Africa
    • 10.6.2.1. By Product Type
  • 10.6.3. Rest of Middle East & Africa
    • 10.6.3.1. By Product Type

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Medtronic
  • 11.2.2. Johnson & Johnson Services, Inc.
  • 11.2.3. Boston Scientific Corporation
  • 11.2.4. AngioDynamics
  • 11.2.5. Abbott
  • 11.2.6. Focal One
  • 11.2.7. Hologic, Inc.
  • 11.2.8. Stryker
  • 11.2.9. Olympus Corporation
  • 11.2.10. Siemens Healthineers AG